ROS1 and small cell lung carcinoma: Based on the above evidence, the observed crizotinib resistance in this case may be related to the following factors: ROS1 kinase conformational changes induced by the rare TBC1D32 fusion partner; the unique biological role of ROS1 fusions in SCLC; and the impact of multiple co-occurring gene mutations.